Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.King Pharmaceuticals, a vertically integrated branded pharmaceutical company, has announced that the US District Court of New York has issued an order invalidating its two US patents relating to Skelaxin.
Subscribe to our email newsletter
The company plans to appeal the order, which was issued in response to Eon’s motion for summary judgment without the benefit of a hearing.
Furthermore, the order is unrelated to the company’s pending litigation against Sandoz, successor to Eon, in the US District Court of New Jersey regarding an additional US patent relating to Skelaxin.
Importantly, Sandoz does not currently have an abbreviated new drug application approved by the FDA to market a generic version of Skelaxin.